Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Avasopasem manganese
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Interim data on first 19 patients released in ASTRO Annual Meeting late-breaker presentation abstract showed improvement in overall survival and multiple anti-cancer efficacy measures .
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 23, 2020
Lead Product(s) : Avasopasem manganese
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
April 21, 2020
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sialidase L
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New study will build on recent clinical evidence showing efficacy of DAS181 in improving symptoms of patients with severe COVID-19.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
April 15, 2020
Lead Product(s) : Sialidase L
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sialidase L
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the first 14 days of study, the first two patients no longer required supplemental oxygen, and showed stabilized vital signs, increased oxygen saturation, and resolution of infiltrates.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
April 02, 2020
Lead Product(s) : Sialidase L
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Renmin Hospital of Wuhan University
Deal Size : Inapplicable
Deal Type : Inapplicable
DAS181 for Severe COVID-19: Compassionate Use
Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 27, 2020
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Renmin Hospital of Wuhan University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 06, 2020
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Tract Infections.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 18, 2019
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Paramyxoviridae Infections.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 19, 2013
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
December 04, 2012
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Paramyxoviridae Infections.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 19, 2012
Lead Product(s) : DAS181
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable